Toshiba's MR Interface Receives FDA Clearance
Toshiba American Systems Inc. today announced FDA clearance of their M-Power interface aimed at increasing MR exam efficiency. The customizable user interface enables technologists to streamline and accelerate the imaging process and enhance diagnosis, according to the company.
Toshiba American Systems Inc. today announced FDA clearance of their M-Power interface aimed at increasing MR exam efficiency. The customizable user interface enables technologists to streamline and accelerate the imaging process and enhance diagnosis, according to the company.
M-Power will be available for use on Toshiba’s Vantage Atlas, Vantage Titan 1.5 and Titan 3T MR systems with the ability to upgrade already-installed systems.
M-Power reduces the steps to start a procedure, and the interface is designed to enhance and personalize work flow. The Atlas Compass software automates coil selection and turns on the proper coil elements needed for an exam. Finally, mVOX, a volume imaging acquisition sequence available for neuro and orthopedic applications, allows the acquisition of all 3D imaging to be acquired at the same time, according to the company.
“M-Power makes Toshiba’s sophisticated suite of MR software easy to learn and use, allowing technologists of every skill level to access the system’s full range of functionality,” Stuart Clarkson, director, MR Business Unit, Toshiba, said in the company release. “MR technologists are now able to design their own protocols and easily access mTools for greater convenience and productivity.”
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
